Any current/future new fundraising through debt or equity?

Sai Life Sciences plans to fund its capex of around INR 700 crores for FY26 through a combination of internal accruals, debt, and remaining funds from the IPO process. There is no specific mention of new equity fundraising; the company intends to utilize the IPO proceeds still available. Debt repayment of INR 720 crores was completed as part of the IPO funds, significantly reducing leverage. Lower interest costs are expected from FY26 due to this reduced leverage. The company balances funding between internal cash flows and debt but has not announced plans for fresh equity issuance.

Any current/future capex/capital investment/strategic investment?

For FY26, Sai Life Sciences plans capex of close to INR 700 crores. Approximately INR 550 crores of this capex is currently planned based on existing visibility, primarily to support fiscal '27 growth. INR 50 to 70 crores of capex is earmarked for new modalities including peptides, ADCs, and oligonucleotides. The remaining balance capex will be triggered based on business visibility throughout the year. Around 60% to 65% of capex will be directed toward manufacturing, and 35% toward R&D. Maintenance capex is roughly INR 70 crores. New manufacturing capacities came online in November and May, i

Future growth expectations in sales/revenue/volumes?

Sai Life Sciences targets long-term revenue growth of 15% to 20% over a 3 to 5-year period. The company plans to achieve EBITDA margins of 28% to 30% within the next couple of years. Revenue growth reflects strong momentum across CDMO and CRO businesses, supported by molecule pipeline scaling up and commercial product volume increases. FY25 revenue grew 16% YoY, with FY26 expected to continue strong growth momentum and improve from 25% EBITDA margin in FY25 to 28%-30% in next 2 years. Capex of about INR700 crores planned for FY26 focused 60-65% on manufacturing and 35% on R&D to support FY27 g

Future growth expectations in earnings/operating earnings/profits/EPS?

Sai Life Sciences targets long-term revenue growth of 15%-20% over a 3-5 year period, reflecting industry cyclicality and pipeline visibility. EBITDA margin guidance is maintained at 28%-30% within the next couple of years. Profit after tax (PAT) for FY25 showed a strong 105% year-on-year increase, supported by operating leverage and cost efficiencies. Return on capital employed (ROCE) is targeted in the mid-to-high teen range as committed during the IPO. The company anticipates increasing capacity utilization and improving operational performance, which support future margin expansion. Capex

Current/ Expected Orderbook/ Pending Orders?

Sai Life Sciences sees strong visibility and increased client flow supporting growth despite a softer global CRDMO environment. (Page 15) Demand is driven primarily by supply chain shifts and long-standing client relationships. (Page 15) The company has observed significant traction in both process development and manufacturing with several molecules scaling up, which is fueling capex expansion. (Pages 9, 10, 15) Current manufacturing capacity utilization is high (~67% in FY25) with a 30% capacity increase expected from new lines coming online between November and May. (Page 6) The pipeline sh

IN US

Sale is live|00:00:00left today

Sai Life Sciences LtdQ1 FY25Pharmaceuticals & Biotechnology

Sai Life Sciences Ltd Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,205P/E: 65.1Market Cap: ₹23.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

Yes

Order

Yes

Capex

Yes

4 of 5 growth signals are positive — a strong management growth story.

Full analysis

Revenue guidance

Category 3

→Sai Life Sciences targets long-term revenue growth of 15% to 20% over a 3 to 5-year period.
→The company plans to achieve EBITDA margins of 28% to 30% within the next couple of years.
→Revenue growth reflects strong momentum across CDMO and CRO businesses, supported by molecule pipeline scaling up and commercial product volume increases.
→FY25 revenue grew 16% YoY, with FY26 expected to continue strong growth momentum and improve from 25% EBITDA margin in FY25 to 28%-30% in next 2 years.
→Capex of about INR700 crores planned for FY26 focused 60-65% on manufacturing and 35% on R&D to support FY27 growth.
→Supply chain shifts favoring India and expanded capacity by 30% expected to support volume growth.
→The business remains cyclical with potential volatility, but balanced across discovery, development, and commercial segments to sustain growth.

Margin guidance

Category 1

→Sai Life Sciences targets long-term revenue growth of 15%-20% over a 3-5 year period, reflecting industry cyclicality and pipeline visibility.
→EBITDA margin guidance is maintained at 28%-30% within the next couple of years.
→Profit after tax (PAT) for FY25 showed a strong 105% year-on-year increase, supported by operating leverage and cost efficiencies.
→Return on capital employed (ROCE) is targeted in the mid-to-high teen range as committed during the IPO.
→The company anticipates increasing capacity utilization and improving operational performance, which support future margin expansion.
→Capex investments of around INR 700 crores for FY26 aim to support growth beyond fiscal year 2027.
→Earnings growth may be lumpy due to the cyclical nature of the CDMO industry and timing of commercial product launches.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→Sai Life Sciences plans to fund its capex of around INR 700 crores for FY26 through a combination of internal accruals, debt, and remaining funds from the IPO process.
→There is no specific mention of new equity fundraising; the company intends to utilize the IPO proceeds still available.
→Debt repayment of INR 720 crores was completed as part of the IPO funds, significantly reducing leverage.
→Lower interest costs are expected from FY26 due to this reduced leverage.
→The company balances funding between internal cash flows and debt but has not announced plans for fresh equity issuance.

Order book

Yes

→Sai Life Sciences sees strong visibility and increased client flow supporting growth despite a softer global CRDMO environment. (Page 15)
→Demand is driven primarily by supply chain shifts and long-standing client relationships. (Page 15)
→The company has observed significant traction in both process development and manufacturing with several molecules scaling up, which is fueling capex expansion. (Pages 9, 10, 15)
→Current manufacturing capacity utilization is high (~67% in FY25) with a 30% capacity increase expected from new lines coming online between November and May. (Page 6)
→The pipeline shows some molecules in late-phase commercial stages; however, exact commercial launch timings are uncertain and out of CDMO control. (Page 10)
→While specific orderbook numbers are not disclosed, the company expresses confidence in sustained pipeline demand and visibility over the next year. (Pages 6, 9, 10, 15)

Capex plans

Yes

→For FY26, Sai Life Sciences plans capex of close to INR 700 crores.
→Approximately INR 550 crores of this capex is currently planned based on existing visibility, primarily to support fiscal '27 growth.
→INR 50 to 70 crores of capex is earmarked for new modalities including peptides, ADCs, and oligonucleotides.
→The remaining balance capex will be triggered based on business visibility throughout the year.
→Around 60% to 65% of capex will be directed toward manufacturing, and 35% toward R&D.
→Maintenance capex is roughly INR 70 crores.
→New manufacturing capacities came online in November and May, increasing capacity by about 30%.
→Capex funding will come from internal accruals, debt, and residual IPO proceeds.
→Investments aim to support pipeline scaling, process development, and expand discovery and manufacturing capabilities.

How does Sai Life Sciences Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Sai Life Sciences Ltd

Rev 3Mar 1

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Sai Life Sciences Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio